Haleon PLC (HLN) AI Stock Analysis

• Market Cap: £32.73B
• Dividend Yield: 1.51%
• Average Volume (3M): 23.77M
• Price to Earnings (P/E): 21.9
• Beta (1Y): 0.30
• Revenue Growth: -2.12%
• EPS Growth: 42.10%
• Country: UK
• Employees: 24,561
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.09
• Shares Outstanding: 8,906,608,000
• 10 Day Avg. Volume: 25,018,353
• 30 Day Avg. Volume: 23,772,072
• PEG Ratio: 0.53
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 3.07
• P/FCF Ratio: 17.37
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £412.20
• Price Target Upside: 12.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: 402.00p ▲(9.39% Upside)

Haleon PLC's overall stock score reflects strong financial performance and positive corporate events, which are the most significant factors. Technical analysis and valuation present a more mixed outlook, with some short-term challenges. The earnings call highlights regional strengths but also points to challenges in North America. Overall, the company is well-positioned for future growth, but careful management of liabilities and strategic initiatives will be crucial.

Positive Factors

Cash Flow Management

Strong cash flow management indicates Haleon's ability to efficiently convert earnings into cash, supporting reinvestment and debt servicing, which is crucial for long-term financial health.

Market Position in EMEA, LatAm, and APAC

Haleon's robust growth in these regions highlights its competitive advantage and market penetration, ensuring sustained revenue streams and market share expansion in diverse geographies.

Gross Margin Improvement

Improved gross margins reflect effective cost management and supply chain productivity, enhancing profitability and providing a buffer against market fluctuations.

Negative Factors

Challenges in North America

Declining sales in North America due to low consumer confidence and inventory pressures could hinder overall growth, requiring strategic adjustments to regain momentum.

Decline in Smokers' Health Segment

The decline in the Smokers' Health segment indicates potential vulnerabilities in product offerings, necessitating innovation or diversification to mitigate impact on overall performance.

Struggles in Pain Relief and VMS Categories

Loss of market share in key categories like Pain Relief and VMS suggests competitive pressures and consumer preference shifts, challenging Haleon to innovate and recapture market position.

Haleon PLC Business Overview & Revenue Model

Company Description

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

How the Company Makes Money

Haleon generates revenue primarily through the sale of its consumer healthcare products across various categories, including oral health, pain relief, respiratory health, and dietary supplements. The company's revenue model is based on direct sales to retail partners, e-commerce platforms, and healthcare professionals. Key revenue streams include the sale of branded OTC medications and health products, which benefit from strong brand loyalty and recognition in the marketplace. Additionally, Haleon engages in strategic partnerships with retailers and distributors to expand its market reach and enhance product availability. The company also invests in marketing and advertising to maintain brand visibility and drive consumer demand, which further contributes to its earnings.

Haleon PLC Financial Statement Overview

Summary

Haleon PLC demonstrates solid financial performance with strong profitability and cash flow metrics. The income statement shows consistent gross profit margins and resilience in net income. The balance sheet is stable, though there is a need for cautious debt management. Cash flow management is robust, with operating cash flow consistently exceeding net income.

Income Statement

Haleon PLC demonstrates solid profitability with gross profit margins consistently around 60% over the years. Net income has shown resilience with a significant increase from 2022 to 2024. The company has also managed steady revenue growth, although there was a slight decline in revenue from 2023 to 2024. EBIT and EBITDA margins remain strong, indicating effective cost management.

Balance Sheet

The balance sheet of Haleon PLC shows a balanced equity position with a stable stockholders' equity. The debt-to-equity ratio is moderate, reflecting a manageable level of debt compared to equity. The equity ratio indicates a solid capital structure, though the total liabilities have increased over the years, suggesting a need for cautious debt management.

Cash Flow

The company has demonstrated strong cash flow management, with operating cash flow consistently exceeding net income, indicating healthy cash generation from operations. Free cash flow has been growing steadily, showing robust capability for reinvestment and debt servicing. The free cash flow to net income ratio highlights efficient conversion of earnings into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.02B	11.23B	11.30B	10.86B	9.54B	9.89B
Gross Profit	6.81B	6.82B	6.75B	6.73B	5.95B	5.91B
EBITDA	2.79B	2.68B	2.67B	2.68B	2.21B	2.19B
Net Income	1.52B	1.44B	1.05B	1.06B	1.39B	1.15B
Balance Sheet
Total Assets	31.83B	34.31B	34.05B	34.81B	34.45B	34.13B
Cash, Cash Equivalents and Short-Term Investments	676.00M	2.19B	1.04B	684.00M	414.00M	334.00M
Total Debt	8.54B	10.10B	9.46B	10.44B	991.00M	487.00M
Total Liabilities	15.83B	18.09B	17.33B	18.36B	7.97B	7.91B
Stockholders Equity	15.94B	16.17B	16.61B	16.33B	26.36B	26.11B
Cash Flow
Free Cash Flow	931.00M	1.98B	1.76B	1.74B	1.06B	1.09B
Operating Cash Flow	1.03B	2.30B	2.10B	2.06B	1.36B	1.41B
Investing Cash Flow	-76.00M	528.00M	-134.00M	-8.78B	-33.00M	1.03B
Financing Cash Flow	-2.52B	-1.54B	-1.57B	6.91B	-1.24B	-2.44B

Haleon PLC Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 367.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HLN, the sentiment is Negative. The current price of 367.5 is below the 20-day moving average (MA) of 369.54, above the 50-day MA of 366.73, and below the 200-day MA of 367.72, indicating a neutral trend. The MACD of 2.04 indicates Positive momentum. The RSI at 48.01 is Neutral, neither overbought nor oversold. The STOCH value of 32.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HLN.

Haleon PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIK	75 Outperform	£3.47B	12.15	15.66%	4.16%	3.73%	27.13%
HLN	73 Outperform	£32.73B	21.86	9.35%	1.51%	-2.12%	42.10%
ANCR	67 Neutral	£174.69M	-7.14	2.83%	2.18%	8.74%	-166.50%
AGY	57 Neutral	£730.83M	-14.17	―	―	-0.28%	22.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Haleon PLC Corporate Events

Haleon Overhauls Operating Model to Accelerate Consumer Health Growth

Haleon plc has announced a major evolution of its operating model to support its “Win as One” strategy, aiming to boost growth, productivity and organisational agility by mid-2026. The company is creating a new Chief Growth Officer role to consolidate its category, marketing, strategy and commercial excellence activities, and a Chief Transformation Officer to oversee extensive changes in business processes, operating structures and technology. In parallel, Haleon will reorganise its geographic structure into six Operating Units, splitting its current EMEA & LatAm region into separate Latin America, Middle East and Africa, and Europe units, while elevating India Subcontinent to its own unit alongside existing North America and Asia Pacific operations. All Operating Unit presidents, together with the new CGO and CTO, will sit on the executive committee and report to CEO Brian McNamara, reflecting a push toward a simpler, more regionally focused and innovation-driven organisation. The company plans to provide further detail with its full-year results in February 2026, and the changes are expected to sharpen execution in key markets and better leverage Haleon’s global brand portfolio, with implications for how it competes in the global consumer health sector.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon Executives Acquire Shares Under Company Reward Plan

Haleon plc has disclosed share transactions by senior executives in line with UK Market Abuse Regulation requirements, confirming that General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 34 partnership shares and received 34 matching shares under the company’s Share Reward Plan. The transactions, conducted on 5 January 2026 on the London Stock Exchange, reinforce equity-based alignment between key management and shareholders, signalling continued use of share-based incentives to tie leadership remuneration to the company’s long-term performance.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon Updates Share Capital and Voting Rights Total

Haleon plc has confirmed that as of 31 December 2025 it has 8,952,353,648 ordinary shares in issue, of which 45,745,646 are held in treasury, leaving 8,906,608,002 ordinary shares carrying voting rights. This updated share capital and voting rights figure provides the reference denominator for investors and other stakeholders when assessing whether they must disclose holdings or changes in positions under UK financial disclosure and transparency regulations.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Announces Leadership Changes in Board and Committees

Haleon PLC has announced significant changes in its board and committee leadership, with Alan Stewart set to become the Senior Independent Director, succeeding Vindi Banga, who will assume the role of Chair effective January 1, 2026. These changes are aligned with the UK Corporate Governance Code 2024, and Vindi Banga’s remuneration as Chair will be £757,103 per annum, as previously disclosed. These leadership adjustments are expected to influence Haleon’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £370.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Discloses Managerial Share Transactions

Haleon PLC announced the notification and public disclosure of transactions by its managerial staff as per UK Market Abuse Regulation. The transactions involved the acquisition of partnership shares and awarding of matching shares under the company’s Share Reward Plan, impacting the company’s stock management and potentially influencing investor perceptions.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £370.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Updates on Total Voting Rights and Share Capital

Haleon PLC announced that as of November 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,882,158 held as treasury shares. This results in 8,906,471,490 shares with voting rights, a figure crucial for shareholders and stakeholders for notification obligations under the FCA’s rules. This announcement is significant for stakeholders as it provides clarity on voting rights and helps in regulatory compliance.

The most recent analyst rating on (GB:HLN) stock is a Sell with a £335.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Discloses Key Managerial Share Transactions

Haleon PLC announced the notification of share transactions by key managerial personnel, Adrian Morris and Tamara Rogers, involving the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan. This disclosure, in line with UK Market Abuse Regulation, underscores Haleon’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market perception.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £517.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon Appoints Vindi Banga as New Chair

Haleon PLC has announced the resignation of Sir Dave Lewis as Chair and the appointment of Vindi Banga as his successor, effective January 1, 2026. Vindi Banga, who has been a Senior Independent Director since Haleon’s listing in 2022, brings extensive global corporate and commercial leadership experience, having previously held significant roles at Unilever and other major companies. This leadership transition is expected to support Haleon’s continued development and strengthen its position in the competitive consumer health industry.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £517.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Updates Total Voting Rights and Share Capital

Haleon PLC announced that as of October 31, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,930,962 held as treasury shares. This results in 8,906,422,686 ordinary shares with voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of notifiable interests in the company.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Haleon PLC Releases 2025 Q3 Trading Statement

Haleon PLC announced the release of its Q3 trading statement for 2025, highlighting its financial performance and strategic initiatives. The statement is accessible on the company’s website and through the Financial Conduct Authority’s National Storage Mechanism. A presentation for analysts and shareholders, led by CFO Dawn Allen, will provide further insights into the company’s operations and future outlook, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (GB:HLN) stock is a Hold with a £3.80 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.